Opinion

Video

Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

The panel compares the ACC/AHA cholesterol guidelines with the ESC/EAS guidelines and provides thoughts on how educational initiatives can be improved to increase familiarity and implementation.

Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
HDL and LDL molecules | Image Credit: © Ratchada - stock.adobe.com
December 19th 2024

FDA Receive a Biologic License Application for Lerodalcibep, a Novel LDL-C-Lowering Drug

Alexandra Gerlach, Associate Editor
Researchers Raise Questions About Low-Carb Diets and Effects on LDL Cholesterol
December 16th 2024

Researchers Raise Questions About Low-Carb Diets and Effects on LDL Cholesterol

Sabina Alikhanov Palmieri, PharmD
Muvalaplin Significantly Lowers Lipoprotein(a) in Adults With High Risk for Cardiovascular Events
December 6th 2024

Muvalaplin Significantly Lowers Lipoprotein(a) in Adults With High Risk for Cardiovascular Events

Aislinn Antrim, Assistant Managing Editor
Cholesterol buildup and blood cells | Image Credit: © VRAYVENUS - stock.adobe.com
December 2nd 2024

Zerlasiran Shows Significant Lipoprotein(a) Reduction in Phase 2 Trial

Alexandra Gerlach, Associate Editor
FCS, Plozasiran, Cholesterol, Familial Chylomicronemia Syndrome| Image Credit: © ugreen | stock.adobe.com
November 22nd 2024

Arrowhead Pharmaceuticals Submits FDA Application for Plozasiran in Familial Chylomicronemia Syndrome

Ashley Gallagher, Associate Editor
AHA 2024: Inclisiran Shows Efficacy, Improved Adherence for Reducing LDL-C
November 17th 2024

AHA 2024: Inclisiran Shows Efficacy, Improved Adherence for Reducing LDL-C

Aislinn Antrim, Assistant Managing Editor